TTY Biopharm Company Limited

4105

TW0004105002

Pharmaceuticals

End-of-day quote Taipei Exchange Other stock markets 18:00:00 2024-05-27 EDT			5-day change	1st Jan Change
77.3 ^TWD	+0.26%		-1.02%	-3.86%

05-10	TTY Biopharm Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-14	TTY Biopharm Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI

TTY Biopharm Company Limited Announces Change of Research and Development Officer

August 12, 2019 at 04:30 am

TTY Biopharm Company Limited announced the replaced person: Hu Yu-Fang, Vice General Manager of Pharmaceutical Development Center with the replacement of Tsai, Shi-Hua, Assist Vice President of Pharmaceutical Development Center (temporary), effective August 12, 2019.

Latest news about TTY Biopharm Company Limited

TTY Biopharm Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
TTY Biopharm Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023	03-14	CI
TTY Biopharm Company Limited Announces Change of CFO and Financial Officer	03-08	CI
TTY Biopharm Company Limited Proposes Cash Dividend for the Year Ended December 31, 2023, Payable on April 26, 2024	03-08	CI
TTY Biopharm Company Limited Appoints Peng,Cheng-Yi as Research and Development Officer, Effective February 01, 2024	01-30	CI
TTY Biopharm Company Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-03	CI
TTY Biopharm Company Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
TTY Biopharm Company Limited Receives Milestone Payment from German Pharmaceutical Company for Co-Development of Liposome Product-Pegylipo in Europe	23-08-09	CI
TTY Biopharm Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
TTY Biopharm Company Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-14	CI
TTY Biopharm Company Limited Proposes Dividend Distribution for the Year Ended December 31, 2022, Payable on May 5, 2023	23-03-14	CI
Aurobindo Pharma Arm Gets US FDA Nod for Amphotericin B Liposome	22-11-18	MT
TTY Biopharm Company Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-04	CI
TTY Biopharm Company Limited Announces Internal Audit Officer Changes, Effective November 7, 2022	22-11-04	CI
TTY Biopharm Company Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-05	CI
TTY Biopharm Company Limited Announces Dividend Distribution, Payable on August 15, 2022	22-07-01	CI
TTY Biopharm Company Limited Announces Cash Dividend for the Year 2021	22-05-26	CI
TTY Biopharm Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-12	CI
TTY Biopharm Company Limited Announces the Resignation of Chou,Te-Yu as Member of Remuneration Committee	22-03-31	CI
TTY Biopharm Company Limited Proposes Cash Dividend for the Year 2021	22-03-09	CI
TTY Biopharm Company Limited Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-08	CI
TTY Biopharm Company Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-03	CI
TTY Biopharm Company Limited Announces Its Generic Drug - Arsenic Trioxide Has Been Approved by US FDA	21-10-17	CI
TTY Biopharm Company Limited Announces Cash Dividend for the Year 2020, Payable on 19 October 2021	21-08-25	CI
TTY Biopharm Company Limited Announces Directors Appointments	21-08-25	CI

Chart TTY Biopharm Company Limited

Duration

Period

More charts

Company Profile

TTY Biopharm Co Ltd is a Taiwan-based company mainly engaged in the research, development, manufacture and sale of pharmaceutical preparations. The Company mainly operates through six business segments including Cancer Drug segment, Healthcare segment, Anti-Infective Drug segment, Domestic Cardiovascular and Gastrointestinal Drug segment, Mainland Medical Drug segment and the Other segment. The main products include oncology medicines, anti-infective medicines and health care medicines. Oncology medicines are mainly anti-cancer and auxiliary drugs. Anti-infective medicines are mainly back-line antimicrobial agents and influenza vaccines. Medical and health care medicines are mainly gastrointestinal health care, bone health care, metabolic health care, infection treatment drugs. The Company distributes its products in domestic and overseas markets.

Sector

Pharmaceuticals

Calendar

2024-05-29 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

77.3 TWD

Average target price

78 TWD

Spread / Average Target

+0.91%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
TTY BIOPHARM COMPANY LIMITED	-3.86%	596M
ELI LILLY AND COMPANY	+38.59%	727B
JOHNSON & JOHNSON	-7.89%	354B
MERCK & CO., INC.	+15.66%	328B
ABBVIE INC.	+0.24%	277B
ASTRAZENECA PLC	+13.47%	243B
NOVARTIS AG	+7.35%	205B
ROCHE HOLDING AG	-6.42%	203B
AMGEN INC.	+4.23%	164B
PFIZER, INC.	-1.70%	164B

Other Pharmaceuticals